Compare Ares Capital Corporation (ARCC) vs Sanofi SA (SNY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ares Capital Corporation vs Sanofi SA — how do they compare? Ares Capital Corporation trades at $18.77 (market cap $13.48B), while Sanofi SA trades at $44.25 (market cap $103.90B). The key difference: Sanofi SA is far larger — about 7.7× Ares Capital Corporation's market cap, and Ares Capital Corporation pays the higher dividend (10.22%). Which is the better fit depends on your goals.
| ARCC | SNY | |
|---|---|---|
Market Cap | $13.48B | $103.90B |
Sector | Financials | Health |
52-Week High | $23.25 | $52.34 |
52-Week Low | $17.45 | $41.33 |
Dividend Yield | 10.22% | 5.56% |
Enterprise Value | — | $120.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ares Capital (ARCC) trades at $18.78, up 2.01% on the day, with a bearish technical signal but strong analyst support. The stock shows a P/E of 11.52 and P/B of 0.96, trading below the consensus price target of $20.58. Recent earnings have missed expectations, with Q2 2026 results pending, while revenue declined to $1.51B in 2025 from $1.7B in 2024. A dividend of $0.48 is scheduled for payment on June 30, 2026, supporting income appeal amid mixed sentiment.
ARCC presents a value opportunity with a high dividend yield and undervaluation relative to analyst targets, but faces headwinds from earnings misses and a bearish technical outlook. Risks include revenue volatility and competitive pressures in the BDC space, though institutional buy ratings suggest confidence in recovery potential. Investors should weigh income stability against growth challenges.
SNY trades at $43.50, down 0.91% today, with a bullish technical signal supported by moving averages. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.10 vs. $1.06 expected, and maintains robust profitability with 71.92% gross margin and 15.95% net margin. Recent FDA approval for Sarclisa's subcutaneous formulation provides growth catalyst.
SNY presents a compelling investment case with solid earnings performance and pipeline advancements, though regulatory scrutiny in Europe and patent expiration risks for key drug Dupixent in 2031 warrant monitoring. Analyst consensus leans positive with 44% buy ratings, supporting a constructive outlook for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
